Theriva Biologics Announces That The THERICEL Project Has Been Awarded Funding Of €2.28 Million From The National Knowledge Transfer Program Of The Spanish Government's Ministry Of Science, Innovation & Universities To Support A Collaboration Between The Universitat Autònoma De Barcelona To Advance The Company's Suspension Cell Platform For The Clinical Manufacture Of Adenovirus- And Adeno-Associated Virus Therapies
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics (NYSE:TOVX) has been awarded €2.28 million from the Spanish government's National Knowledge Transfer Program to support a collaboration with Universitat Autònoma de Barcelona. The funding will advance Theriva's suspension cell platform for manufacturing virus therapies.
September 16, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theriva Biologics has secured €2.28 million funding from the Spanish government to collaborate with Universitat Autònoma de Barcelona. This will enhance their suspension cell platform for virus therapies, potentially boosting their product development and revenue.
The funding supports a key collaboration for advancing Theriva's technology, which is crucial for their product development. The financial support and partnership with a reputable institution like Universitat Autònoma de Barcelona are likely to positively impact Theriva's capabilities and future revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90